Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...
Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...
Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...
Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...
Gilead Sciences, Inc. (GILD) Stock Sees Market Value Hit $115.13 billion: What Are the Implications?
BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...
Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey and ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback